One of Geiser Pharma last’s developments is ready to license out!

We expand the portfolio of cough&cold products with a combination of 3 mg of benzydamine hydrochloride and 1 mg of cetylpyridinium chloride.

The anti-inflammatory and analgesic properties of benzydamine, together with the antiseptic pnes of cetylpyridinium, make these mint-flavored lozenges a perfect combination that contribute to the relief of symptomatic pain in the oral cavity. This lozenge disinfects the mouth and throat and reduces signs of inflammation of throat such as pain, redness, swelling, heat and impaired function. 

This OTC product is intended for anti-inflammatory, analgesic and antiseptic treatment of sore throat associated with upper respiratory infections including pharyngitis in adults and children from 6 years of age.

Geiser Pharma experience in the development of cough&cold lozenges and in benzydamine molecule, allow to offer a high quality dossier and finished dosage form, that together with client brand will become a success in the market.

Under our licensing out business model, we always seek through a win-win strategy, partnerships with which we can reach license and supply agreements that boost both parties’ growth